IMUNON, Inc. unveiled its new current Good Manufacturing Practices (cGMP) clinical materials production facility, located on the Huntsville campus of the HudsonAlpha Institute for Biotechnology. The facility is intended to provide IMUNON with additional control over the quantities and costs of manufacturing non-viral DNA-based materials used in its research and development (R&D) activities.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.355 USD | -5.92% | +6.68% | +99.24% |
Apr. 18 | Imunon Receives FDA Approval to Start Phase 1 Trial of COVID-19 Booster Vaccine | MT |
Apr. 18 | Imunon Shares Rise 8% After Clearance to Start Phase 1 Trial for Covid-19 Booster Vaccine | DJ |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+99.24% | 13.54M | |
-2.63% | 103B | |
+1.62% | 95.28B | |
+1.46% | 22.15B | |
-16.67% | 21.02B | |
-8.58% | 18.15B | |
-38.74% | 16.73B | |
-13.21% | 16.05B | |
+5.41% | 13.68B | |
+33.57% | 12.17B |
- Stock Market
- Equities
- IMNN Stock
- News Imunon, Inc.
- IMUNON, Inc. Unveils New Manufacturing Capabilities at Huntsville's HudsonAlpha Biotech Campus